Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: The present invention provides a method of treating or preventing a disorder typified by an immunodificiency (e.g. HIV), wherein the patient is administered a COX-2 inhibitor or derivative or pharmaceutically acceptable salt thereof, preferably diisopropylfluorophasphate. L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib or nimesulide, and compositions and products containing the same or use of the same in preparing medicaments and for treatment.

Abstract: The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.

Abstract: Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.

Abstract: Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.

Abstract: The present invention relates to fatty acid analogues of the general formula I: R1-[xi-CH2]n—COOR2; wherein R1 is; a C1-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or, a C1-C24 alkyne, and/or, a C1-C424 alkyl, or a C1-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy or C1-C4 alkyl, and; wherein R2 represents hydrogen or C1-C4 alkyl, and; wherein n is an integer from 1 to 12, and; wherein i is an old number and indicates the position relative to COOR2, and; wherein Xi independent of each other are selected from the group comprising, O, S, SO, SO2, Se and CH2, and; with the proviso that at least one of the Xi is not CH2; which can be used for the treatment and/or prevention of inflammatory disorders.

Abstract: The present invention relates to the use of an immunomodulating agent, in particular intravenous immunoglobulin (IVIG), in the manufacture of a medicament for use in the treatment of non-viral or non-autoimmune induced heart disorders or non-viral or non-autoimmune associated phases of heart disorders or the symptoms associated therewith. Particular heart disorders to be treated are selected from the group comprising chronic CHF, chronic (stable) angina pectoris and acute coronary syndromes. Pharmaceutical compositions for use in the treatment of such disorders comprising immunomodulating agents are also provided.